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Calcineurin inhibitors (CNIs) form the foundation of current graft-versus-host disease (GVHD) prophylaxis
regimens. We hypothesized that a CNI-free regimen consisting of post-transplantation cyclophosphamide
(PTCy) and brief-course sirolimus would reduce chronic GVHD and nonrelapse mortality (NRM) after
reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation (PBSCT). Twenty-six
patients (median age, 61 years) underwent unmanipulated PBSCT from an 8/8 locus-matched donor
(matched related donor, n ¼ 17; natched unrelated donor, n ¼ 9). GVHD prophylaxis consisted of PTCy and
brief-course sirolimus. Donor engraftment occurred in all patients. The cumulative incidence (CI) of grade
II-IV acute GVHD, grade III-IV acute GVHD, and chronic GVHD was 46%, 15%, and 31% respectively. One-year
NRM was 4%. The median time to immunosuppression discontinuation was day þ138. With a median follow-
up of 20 months, the estimated 2-year overall survival was 71%, estimated disease-free survival was 64%, and
estimated relapse incidence was 32%. In patients with a lymphoid malignancy (eg, chronic lymphoblastic
leukemia, non-Hodgkin lymphoma, Hodgkin disease), 2-year disease-free survival was 100%, and there were
no relapses. Good immune reconstitution was evidenced by low cytomegalovirus reactivation rate of 21% (4 of
19 at-risk patients). GVHD prophylaxis with PTCy and sirolimus achieves consistent donor engraftment, low
rates of chronic GVHD and NRM, and excellent outcomes in recipients of HLA-identical related and unrelated
donor allogeneic PBSCT.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (HSCT)
is a potentially curative treatment for various hematologic
malignancies and nonmalignant hematologic disorders [1].
The efﬁcacy of treatment has been attributed to both the high-
dose chemotherapy preparative regimen and the induction of
a graft-versus-malignancy effect by immunocompetent cells
in the graft [2]. Conventional myeloablative conditioningmay
be associated with unacceptably high toxicity and nonrelapse
mortality (NRM) in elderly, sick, orheavily pretreatedpatients.
The use of reduced-intensity conditioning (RIC) has allowed
extension of this treatment to a much wider patient popula-
tion by reducing the toxicity and exploiting the graft-versus-edgments on page 1833.
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ty for Blood and Marrow Transplantation.malignancy effect as the primary curative approach [3,4].
Nonrandomized studies have shown similar outcomes from
allogeneic HSCT with RIC and allogeneic HSCT with conven-
tional myeloablative conditioning, with decreased morbidity
and NRM balanced by a higher rate of disease relapse [5-7].
Despite the fact that outcomes for patients receiving RIC
allogeneic matched related or unrelated donor HSCT have
continued to improve over time owing to improvements in
transplantation techniques and supportive care, GVHD re-
mains a major source of post-transplantation morbidity and
mortality. Although advances in immunosuppressive regi-
mens have had some impact on the incidence and severity of
acute GVHD, they have had little impact on the incidence and
severity of chronic GVHD [8-12]. In fact, chronic GVHD has
become one of the most common and clinically signiﬁcant
problems affecting long-term HSCT survivors, occurring in
up to 70% of patients surviving more than 100 days post-
transplantation. Management of chronic GVHD remains a
Figure 1. Treatment protocol schemata.
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lem in HSCT survivors with the increasing use of mobilized
peripheral blood stem cells [13,14].
The combination of calcineurin inhibitors (CNIs), such as
tacrolimus or cyclosporine, withmethotrexatewas developed
more than 3 decades ago and remains the most common
regimen used for GVHD prophylaxis. Although CNI-based
immunosuppression has resulted in satisfactory rates of
acute GVHD and survival outcomes, these regimens are not
uniformly effective, and many patients are still dying from
GVHD and related complications. Furthermore, these regi-
mens are associated with considerable toxicity, namely renal
dysfunction. Thus, there is considerable room for improve-
ment in CNI-based regimens.
CD4þCD25þFoxp3þ regulatory T cells (Tregs) are a func-
tionally distinct subset of mature T cells with broad suppres-
sive activity. In the setting of allogeneic HSCT, Tregs also have
been shown to play an important role in the establishment of
tolerance between recipient tissues and donor-derived im-
munity. This was initially demonstrated in murine studies in
which depletion of Tregs from the stem cell graft resulted in
increased GVHD and increasing Tregs resulted in suppression
of GVHD after transplantation [15-18]. In humans, patients
with active GVHD have a lower frequency of Tregs compared
with thosewithout GVHD [19-21]. These ﬁndings suggest that
robust reconstitutionof Tregs afterHSCT is needed to establish
a well-balanced immune system that can maintain appro-
priate levels of peripheral tolerance.
Current evidence suggests that CNIs, such as tacrolimus
and cyclosporine, have markedly negative effects on Treg
reconstitution, whereas other agents, such as sirolimus and
mycophenolate mofetil, may actually promote Treg recovery
post-transplantation [22,23]. The use of post-transplantation
cyclophosphamide (PTCy) for GVHD prevention without the
use of CNIs also has been reported to preserve Treg recovery
[24]. We hypothesized that a CNI-free regimen consisting of
PTCy and brief-course sirolimus would decrease the risk of
chronic GVHD and the need for long-term immunosup-
pression after HSCT, resulting in lower NRM and improved
outcomes after RIC allogeneic peripheral blood stem cell
transplantation (PBSCT).PATIENTS AND METHODS
Patients and Donors
Twenty-six patients were accrued to this prospective phase II single-
institution clinical trial. Written informed consent was obtained for each
patient in accordance with the Declaration of Helsinki. The study was
approved by the Institutional Review Board of Northside Hospital. Patients
were eligible for inclusion if theywere between 18 and 75 years of age, had a
standard indication for RIC allogeneic HSCT and an available matched
related or unrelated donor, and had adequate organ function (as deﬁned by
bilirubin <2, creatinine <2, cardiac ejection fraction 40%, pulmonary
function 50% of predicted, and Karnofsky performance status 70%), and
were HIV-negative. Related or unrelated donors were 8/8 HLA matched
(HLA-A, -B, -C, -DR) with the recipient.Conditioning Regimen and Postgraft Immunosuppression
Pretransplantation conditioning consisted of ﬂudarabine 30 mg/m2/day
on days9 to6, i.v. busulfan 130 mg/m2/day on days5 to4, and Cy 14.5
mg/kg/day on days 3 and 2. On day 0, patients received an unmanipu-
lated PBSC allograft with a CD34 dose capped at 5106/kg recipient weight.
On days þ3 and þ4, patients received 2 doses of Cy 50 mg/kg/day with
Mesna. No immunosuppressive agents, including corticosteroids, were
administered until 24 hours after the last dose of PTCy. Sirolimus was
initiated on day þ5 post-transplantation. The ﬁrst 7 patients received a
loading dose of 2.0 mg, followed by a daily dose of 0.5 mg/day, and the next
19 patients received a loading dose of 4.0 mg, followed by a daily dose of 1.0
mg/day. Sirolimus was then targeted to achieve a trough level of 3-12 ng/mLand was discontinued without taper at day þ90 to þ100, in the absence of
GVHD. The transplantation regimen is depicted schematically in Figure 1.
Supportive Care
Antimicrobial prophylaxis was administered according to institutional
practice guidelines starting on day 0 and included a quinolone antibiotic and
acyclovir. Antifungal prophylaxis consisted of an echinocandin (caspofungin
or micafungin) up to dayþ5, then a change to oral therapy with ﬂuconazole,
voriconazole, or posaconazole. Filgrastim 5 mg/kg was given daily starting on
day þ5 and continuing until neutrophil engraftment. Standard prophylaxis
for Pneumocystis jiroveciiwas started on dayþ30 and continued for at least 6
months post-transplantation and until immunosuppression was dis-
continued. Quantitative cytomegalovirus (CMV) PCR was monitored weekly
starting on dayþ1, and preemptive therapy was initiated if viral reactivation
was detected (800 copies/mL).
Chimerism Analysis
We assessed donorerecipient chimerism through PCR-based ampliﬁ-
cation of a polymorphic short tandem repeat regions, followed by fragment
separation by high resolution capillary electrophoresis (ABI 3130 XL Genetic
Analyzer; Life Technologies, Grand Island, NY) and quantitation using
GeneMapper Software (Life Technologies). Peripheral blood samples were
collected for chimerism analysis on days þ30, þ60, and þ90. Samples were
separated intomyeloid and Tcell lymphoid fractions by indirect sorting with
immunomagnetic beads (Stem Cell Technologies, Vancouver, BC, Canada).
Primary antibodies were speciﬁc to CD33 and CD66b for myeloid cell frac-
tionation and to CD3 for lymphoid T cell fractionation. The quality of sort
was assessed using multiparametric ﬂow cytometry (FACSCanto cytometer
and DIVA analysis software; BD Biosciences, San Jose, CA). Genomic DNAwas
extracted from immunosorted cells, andmultiplex PCRwas performed using
commercial ﬂuorescently labeled primer sets (ProﬁlerPlus and Coﬁler NGM
Kits; Life Technologies). Four- or 5-color ﬂuorescence detection was per-
formed on an ABI 3130 XL Genetic Analyzer and quantiﬁed using Gene-
Mapper software. For each informative short tandem repeat locus, allelic
peak heights were determined, and the percentage of host alleles was
calculated as [S(host alleles peak height))/(S(host þ donor alleles peak
heights)]  100. The range of the error of chimerism was determined to be
nonuniform between different levels of chimerism and did not exceed 3.23%
for 1%-5% host, 6.66% for 6%-20% host, 8.33% for 21%-40% host, 8.89% for 41%-
60% host, 8.60% for 61%-80% host, 5.31% for 81%-95% host, and 3.07% for 95%-
99% host. Ranges for chimerism error assessment were selected empirically
in our laboratory.
Deﬁnitions and Study Endpoints
Neutrophil engraftment was deﬁned as the ﬁrst of 3 days of an absolute
neutrophil count of >0.5  109/L after transplantation. Platelet engraftment
was deﬁned as a platelet count of >20,000/mL without transfusion for the
preceding 7 days. Acute GVHD was scored based on the modiﬁed Keystone
criteria [25]. Grade III-IV GVHDwas considered severe GVHD. Chronic GVHD
diagnosis and grading were based on the National Institutes of Health
consensus criteria [26]. Patient outcomes are reported as of December 31,
2013. The major study endpoints were sustained donor engraftment, inci-
dence and severity of GVHD, and NRM. Patients were considered to have
died of NRM if there was no evidence of disease relapse or progression
before death.
Statistical Methods
Probabilities of overal survival (OS) and disease-free survival (DFS) were
estimated using the Kaplan-Meier product-limit method [27]. The cumu-
lative incidences of NRM, relapse, acute GVHD, and chronic GVHD were
computed to take into account the presence of competing risks [28]. The log-
rank test was used to compare DFS between patients with lymphoid ma-
lignancies and other patients. The Gray test [29] was used to compare the
incidence of relapse between these 2 groups. A survival outcome was
determined to be signiﬁcantly different between the 2 groups if the
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immunosuppression was smoothed by the Lowess method, and the Lowess
curve was depicted.RESULTS
Patient Characteristics
A total of 26 patients (median age, 61 years; range, 25-73
years) with a high-risk hematologic malignancy were treated
between March 2011 and March 2013. Patient characteristics
are summarized in Table 1. Seventeen patients received a
transplant from a matched sibling donor, and the other 9
received a matched unrelated donor transplant. All donors
and recipients were 8/8 allele matched at HLA-A, -B, -C, and
-DR. Ten patients underwent transplantation for a lymphoid
malignancy (non-Hodgkin lymphoma [NHL], Hodgkin dis-
ease [HD], chronic lymphoblastic leukemia [CLL]), 7 with
chemotherapy-refractory relapse or progressive disease at
the time of transplantation. The remaining 16 patients un-
derwent transplantation for acute myelogenous leukemia
(AML; n ¼ 8), myelodysplastic syndrome (MDS; n ¼ 3),
myeloproliferative neoplasm (MPN; n ¼ 4), or acute lym-
phocytic leukemia (ALL; n¼ 1). Of the 22 patients classiﬁable
by the Center for International Blood and Marrow Transplant
Research disease risk index, 9 (41%) were high risk, 6 (27%)
were intermediate risk, and and 7 (32%) were low risk. The 4
patients with MPN were risk-stratiﬁed by the International
Prognostic Scoring System as intermediate 2 risk (n ¼ 2) and
high risk (n ¼ 2).Engraftment and Chimerism
Donor engraftment occurred in all 26 patients, with a
median time to neutrophil recovery of 15 days (range, 13-28
days) and to platelet recovery of 30 days (range,16-164 days).
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* ASBMT RFI disease risk corresponding to CIBMTR classiﬁcations.
Patients with MPN are not classiﬁable.donor T cell chimerism was 94% (range, 40%-100%) and
median myeloid chimerism was 100% (range, 11%-100%)
(Figure 2). Three patients received donor lymphocyte in-
fusions for incomplete donor T cell chimerism. Full donor
chimerism (ie, >95% donor T cells and myeloid cells) was
achieved in all but 2 evaluable patients by day þ180. In both
cases, decreasing donor myeloid chimerism was associated
with full donor Tcell chimerism and progression of amyeloid
malignancy.Sirolimus Trough Levels, Regimen-Related Toxicity, and
Infectious Complications
Sirolimus was started on day þ5 with a plan to discon-
tinue the drug without taper at day þ90 to day þ100 in the
absence of GVHD. Three patients discontinued sirolimus
early (on days þ54, þ66, and þ76) owing to frank AML
relapse, myeloﬁbrosis decreasing donor myeloid chimerism,
and incomplete donor T cell chimerism. Therapeutic siroli-
mus trough levels of 3-12 ng/mL were achieved 78% of the
time (<3 ng/mL, 6%; 3-7.9 ng/mL, 47%; 8-12 ng/mL, 31%; >12
ng/mL, 16%). The median sirolimus trough level was 7.6
ng/mL, and the mean sirolimus trough level was 8.4 ng/mL.
Eight patients (31%) required a switch from sirolimus to
tacrolimus at a median of day þ51 (range, day þ23 to þ90)
due to GVHD (n ¼3), cytopenias (n ¼2), or hepatic sinusoidal
obstruction syndrome (SOS) (n¼2). Therewas no association
between sirolimus level and the development of acute or
chronic GVHD. In the 4 patients who switched from sirolimus
to tacrolimus because of cytopenias (n ¼ 2) or hepatic SOS
(n ¼ 2), sirolimus trough levels were10 ng/mL on at least 2
consecutive trough levels immediately before the switch in 2Figure 2. Kinetics of lineage-speciﬁc peripheral blood donor cell chimerism
for (A) T cells and (B) myeloid cells.
Figure 4. Time to discontinuation of immunosuppression.
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hepatic SOS.
Two patients had reversible nonfatal hepatic SOS, asso-
ciated with transaminase elevation and ascites but without
hyperbilirubinemia. Both cases reversed spontaneously after
discontinuation of sirolimus and a switch to tacrolimus.
Nephrotoxicity (deﬁned as 1.5 times the upper limit of
normal) was uncommon, occurring in only 2 patients (7.7%).
Sirolimus-associated adverse events, such as thrombotic
microangiopathy, severe hypertriglyceridemia (>3 times the
upper limit of normal), and arthralgias, were not seen. CMV
reactivationwas uncommon, occurring in only 4 of 19 at-risk
patients (21%). There were no cases of CMV disease or
Epstein-Barr virus post-transplantation lymphoproliferative
disorder. No invasive mold infections were detected in the
ﬁrst 6 months post-transplantation. BK viruseassociated
cystitis occurred in 8 patients (31%) and was clinically sig-
niﬁcant (ie, requiring hospital admission for bladder irriga-
tion and/or pain management) in 4 of them (15%). It resolved
in all cases.
GVHD and Time to Immunosuppression Discontinuation
The cumulative incidence of grade II-IV acute GVHD was
46%, and that of grade III-IV acute GVHDwas 15% (Figure 3A).
Eight patients developed extensive chronic GVHD at a me-
dian of 125 days post-transplantation (range, 101-186 days).
The cumulative incidence of extensive chronic GVHD was
31% (Figure 3B). The median time to discontinuation of
immunosuppression was 138 days (range, 54-794 days). The
proportion of patients remaining on immunosuppression
was 37% (7/19) at 1 year post-transplantation and 11% (1/9)
at 2 years post-transplantation (Figure 4).Figure 3. Cumulative incidence of (A) acute GVHD and (B) chronic GVHD.Relapse, NRM, DFS, and OS
The cumulative incidence of NRM was low, 4% at 1 year
post-transplantation. With a median follow-up of 20 months
(range 11.2-33.5 months) for surviving patients, 2-year esti-
mated OS was 71%, DFS was 64%, relapse was 32%, and NRM
was 13% (Figure 5). A subset analysis revealed lower risk for
relapse and improved DFS in patients undergoing trans-
plantation for a lymphoid malignancy (HD, NHL, or CLL)
compared with those undergoing transplantation for a
myeloid malignancy or ALL (2-year relapse risk, 0% versus
51%, P ¼ .011; 2-year DFS, 100% versus 43%, P ¼ .020)
(Figure 6). At the time of this report, 18 patients were alive,16
of whom remained disease-free. Of the eight deaths in the
study cohort, 6 were related to relapse of AML (n ¼ 5) or ALL
(n ¼ 1). There were 2 nonrelapse deaths, 1 due to acute lungFigure 5. Kaplan-Meier analysis of (A) OS, DFS, and NRM and (B) relapse
incidence.
Figure 6. Kaplan-Meier analysis of (A) DFS and (B) relapse incidence accord-
ing to disease. The probability of DFS and relapse were compared between
patients undergoing transplantation for a lymphoid malignancy (HD, NHL, or
CLL) and those undergoing transplantation for another lymphoid malignancy
(AML, MDS, MPN, or ALL).
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infection in the context of treatment for chronic GVHD on
day þ794 in a patient undergoing transplantation for re-
fractory CLL.
DISCUSSION
Here we report on a prospective trial designed to test
whether a CNI-free GVHD prophylaxis strategy consisting of
PTCy and brief-course sirolimus is a safe and effective alter-
native to standard CNI-based immunosuppression after RIC
allogeneic PBSCT. We hypothesized that CNI-free GVHD pro-
phylaxis may improve outcomes by reducing the incidence
and severity of chronic GVHD and, by extension, the require-
ment for long-term therapy with immunosuppressive drugs.
Despite the advanced age of the patients accrued (median age,
61 years) and the relatively poor risk status of their malig-
nancies (the majority with high- and intermediate-risk dis-
ease), NRMwas lowat only 4% at 1 year. This approach also led
to consistent donor engraftment, low rates of CMV and in-
fectious complications, and a low incidence of chronic GVHD,
allowing more rapid withdrawal of immunosuppression.
Relapse and DFS were acceptable compared with historical
experience of RIC allogeneic HSCT for high-risk hematologic
malignancies. Results appear particularly promising in pa-
tients with lymphoproliferative disorders such as HD, NHL,
and CLL (2-year DFS,100%; 2-year relapse, 0%), despite the fact
that 70% of these patients had chemorefractory disease at the
time of transplantation.
High-dose Cy is a potent immunomodulatory agent that
has been used to prevent GVHD in the HLA-matched and
HLA-mismatched setting in several single-center andmulticenter studies [30-35]. Preclinical studies have shown
that Cy administered early after HSCT preferentially kills
activated, cycling alloreactive T cells while sparing resting,
nonalloreactive T cells, leading to suppression of GVHD as
well as graft rejection [36,37] Furthermore, a recent study
showed that human regulatory T cells are resistant to PTCy
and may contribute to its GVHD preventive effects [24].
Sirolimus, although structurally similar to tacrolimus,
binds to a distinct site of the FK506-binding protein. It forms
a complex that inhibits the mammalian target of rapamycin
(mTOR). It also inhibits cell cycle entry in response to IL-2,
leading to T cell apoptosis [38]. Sirolimus’ unique proper-
ties give it potential advantages over other immunosup-
pressive agents, including inhibition of T cell function while
at the same time promoting CD4þCD25þFoxP3þ regulatory T
cells [22,39], inhibition of antigen presentation and dendritic
cell maturation [40-42], antiﬁbrotic properties [43,44],
antineoplastic activity [45-47], antiviral activity [48,49], and
minimal nephrotoxicity. The combination of PTCy and siro-
limus has been shown to be synergistic and effective in a
preclinical mismatched murine transplant model [50].
The combination of PTCy and brief-course sirolimus was
well tolerated in this study, with grade 1 renal toxicity
(deﬁned as >1.5 times the upper limit of normal) in only 2
patients and no cases of thrombotic microangiopathy. CMV
reactivationwas uncommon, occurring in only 4 of 19 at-risk
patients (21%). A few signiﬁcant toxicities were seen in these
patients, which included 2 cases of reversible nonfatal he-
patic SOS and 4 episodes of clinically signiﬁcant BK
viruseassociated cystitis requiring hospital admission for
bladder irrigation and/or pain management.
Although sirolimus was well tolerated in the majority of
patients, 8 patients (31%) did require a switch from sirolimus
to tacrolimus before day þ90. Reasons for switching immu-
nosuppression included the development of GVHD (n ¼ 3),
cytopenias (n ¼ 2), and hepatic SOS (n ¼ 2). In all 8 cases, the
change in immunosuppression from sirolimus to tacrolimus
was accompanied by improvement and/or resolution of these
complications. The 2 cases of reversible hepatic SOS in this
study occurred in heavily pretreated patients (1 with re-
fractory CLL and 1 with refractory HD after a previous autol-
ogous transplantation). Both cases presented with a
transaminitis, ascites, and weight gain and required diuretics
and paracentesis for management. Hyperbilirubinemia was
not documented in either case, and both patients improved
within a fewweeks of sirolimus discontinuation. In 1 of these
patients, the sirolimus trough level measured before the
occurrence of hepatic SOSwashigh (20ng/mL),whereas in the
other case, trough levels were within the therapeutic range.
The use of sirolimus in GVHD prophylaxis has been associated
with an increased risk of hepatic SOS in other studies [51-54]
and may be related to sirolimus trough level [53].
The incidence of chronic GVHD in this study of 31%
compares favorably with the 55%-70% incidence reported
after T cellereplete matched donor PBSCT and standard CNI-
based GVHD prophylaxis [13,14,55-57]. Note, however, that
the incidence is higher than the 10%-20% incidence reported
after haploidentical HSCT using bonemarrowas the stem cell
source and PTCy with tacrolimus/mycophenolate mofetil for
GVHD prophylaxis [31,33]. Historically, patients typically
remain on a CNI for at least 6 months post-transplantation
unless GVHD develops, in which case it extended, usually
in combination with corticosteroids. A retrospective analysis
of 751 patients with chronic GVHD found a median duration
of immunosuppression following the diagnosis of chronic
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immunosuppressive drugs after 7 years [58]. In this context,
CNI-free GVHD prophylaxis with PTCy and brief-course
sirolimus allowed rapid withdrawal of immunosuppression,
with a median time to discontinuation of immunosuppres-
sion of 138 days. The percentage of patients still requiring
immunosuppression was 37% at 1 year post-transplantation
and 11% at 2 years post-transplantation.
The overall 2-year risk of relapse (32%) and DFS (64%)
were consistent with the historical experience of RIC
allogeneic HSCT for high-risk hematologic malignancies
[7,59-63]. In patients with AML/MDS, the reported risk of
relapse after RIC allogeneic HSCT is 37%-50%, with 2-year DFS
rates of approximately 43%-45% [7,60,63]. In patients with
lymphoproliferative disease (ie, NHL, HD, and CLL), the risk of
relapse after RIC allogeneic HSCT is 36%-50%, with 1-year DFS
rates of approximately 46%-48% [59,61,62]. In patients with
lymphoma, chemosensitivity before transplantation holds
signiﬁcant prognostic value, with chemoresistant patients at
greater risk for relapse compared with chemoresponsive
patients (1-year relapse risk, 75% versus 25%; P ¼ .001) [61].
In our series, patients with lymphoid malignancies
demonstrated favorable outcomes (2-year relapse and DFS of
0% and 100%, respectively), despite the fact that the majority
of these patients had chemoresistant disease before trans-
plantation. Although numbers are too small to allow us to
draw deﬁnitive conclusions, these data suggest that PTCy
and sirolimus may provide superior disease control for pa-
tients with lymphoproliferative disease compared with
conventional CNI-based GVHD prophylaxisda concept that
could be tested further in a larger randomized controlled
trial. Inhibition of mTOR has demonstrated preclinical ac-
tivity against mantle cell lymphoma [64], CLL [65], Hodgkin
lymphoma [66], and diffuse large B cell lymphoma [67],
among others. Furthermore, 2 mTOR inhibitors, temsir-
olimus and everolimus, have shown promising clinical
activity against relapsed or refractory lymphoma [68-71].
Also supporting our ﬁndings, Armand et al. [45] reported
improved survival and decreased relapse/progression in pa-
tients with lymphoma receiving sirolimus for GVHD pro-
phylaxis after RIC allogeneic HSCT.
CNI-free GVHD prophylaxis with PTCy and brief-course
sirolimus appears to be a safe and effective alternative to
standard CNI-based immunosuppression after RIC allogeneic
PBSCT. Potential beneﬁts include reduced renal toxicity,
improved immune reconstitution manifested by low risk of
infectious complications, modest rates of GVHD, and rapid
discontinuation of immunosuppressive therapy. Given the
older age and high-risk nature of this patient cohort, out-
comes appear favorable, with very low rates of NRM and
promising survival.ACKNOWLEDGMENTS
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